$VEEV

Schwenger Thomas D. sold $2.8M of VEEV

Schwenger Thomas D. (Pres. & Chief Customer Officer) sold 10,000 shares of VEEVA SYSTEMS INC (VEEV) at $281.33 ($2.81M total) on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schwenger Thomas D.
Published Aug 31, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VEEV
Bearish
medium confidence
Mentioned
$VEEV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VEEVBearishLow
01

Why it matters

The disclosed sale provides fresh data for traders assessing short‑term price direction.

02

Market read

First‑report insider transaction; modest relevance for short‑term traders.

03

What to watch

The insider's remaining stake still represents a significant ownership percentage.

Relevance 5/10Novelty 5/10Timing: post‑market 2026‑08‑27

Background

Veeva Systems filed a Form 4 reporting an insider sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$VEEVBearishMedium confidence
Context

Form 4 shows President & Chief Customer Officer sold 10,000 shares for $2.8M, reducing his stake to 19,449 shares.

Expected impact

Possible modest decline over the next few days as market digests the sale.

Evidence & confidence

The insider holds a senior role and sold a sizable block; such sales often lead to short-term sell pressure.

Market effects

Minimal impact on the broader health‑care software sector.

U.S. market only; no regional ripple.

Low global relevance.

Counterpoint

The sale could be a routine portfolio rebalancing, not a bearish signal.

Key entities

  • Thomas D. Schwenger

    President & Chief Customer Officer of Veeva Systems.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VEEVMed

CFRA upgrades Veeva Systems (VEEV) to a Buy

CFRA upgraded Veeva Systems (VEEV) to Buy with a new price target. The consensus rating is Moderate Buy with an average target of $293.57. Veeva reported Q2 revenue of $927.96M and net profit of $273.43M, up from $789.08M and $200.31M last year. Insider sentiment is negative, with 63 insiders selling shares.

$VEEVHighAI 8/10

Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock.

Veeva Systems reported a 37% increase in net income to $273.4M and raised fiscal 2027 revenue guidance to $3.682B-$3.687B. Michael Burry trimmed his position but remains bullish, citing the company's intrinsic value and growth potential. Analysts expect Q3 EPS of $1.68 and have raised price targets, with a consensus 'Moderate Buy' rating and $292.52 average target.

$VEEVMedAI 8/10

Veeva Rises on Sales and Margin Gains, Guidance Raise

Veeva Systems (VEEV) reported Q2 fiscal 2027 revenue of $928M, up 18% YoY, with non-GAAP operating income of $415.9M. The company raised guidance to $3.687B in revenue and $9.21 in non-GAAP EPS. VEEV shares have risen 25% YTD, supported by strong institutional demand and robust fundamentals, including 3-year sales and EPS growth rates of 14.1% and 21.6%, respectively.

$VEEVHighAI 8/10

Watch Veeva, CrowdStrike, and More

Veeva Systems (VEEV) reported Q2 non-GAAP EPS of $2.35, revenue growth of 17.6% Y/Y to $928M, and raised its Q3 revenue forecast. CrowdStrike (CRWD) posted 25.6% Y/Y revenue growth to $1.47B. Dycom Industries (DY) fell 11.6% despite 45.6% Y/Y revenue growth to $2.01B due to segment pressures and higher costs.

$VEEVHighAI 8/10

Veeva (VEEV) Q2 2027 Earnings Call Transcript

Veeva Systems (VEEV) reported Q2 2027 revenues of $928.0 million, up 18% YoY, driven by growth in commercial and R&D segments. Subscription revenues rose 16% to $766.8 million. Non-GAAP operating income was $415.9 million, with a 44.8% margin. The company raised FY 2027 revenue guidance to $3.682B-$3.687B and EPS guidance to $9.21. Management highlighted strong adoption of Vault CRM and Data Cloud solutions, with 12 top 20 biopharmas committed to Vault CRM. Risks include the launch of the new Fa